Ono Pharma developing new diagnostic for potential Opdivo patients

Japan's Ono Pharmaceutical is planning to develop a new diagnostic tool to determine whether more cancer patients will benefit from the cancer drug Opdivo. The company has put together a team of 6 researchers to ID cancer biomarkers; it has already found one marker that "determines how well a patient could respond to the drug." Opdivo was approved in Japan in 2014 for melanoma treatments and in 2015 for lung cancer. A Nikkei report said the company earned $21 million from Opdivo sales in 2014 and that a new diagnostic tool could increase sales. The approach differs from conventional treatments because it looks for patients with specific genetic codes, but this entails a "companion diagnostic" to ID benefits and side effects. Report

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.